David Walsh

Cooley advised Atsena Therapeutics, a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases, on the close of its oversubscribed $150 million Series C financing.

Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.

Cooley advised Takara Bio, a global biotechnology and life sciences company headquartered in Shiga, Japan, on its acquisition of Curio Bioscience, a pioneering company in the field of spatial genomics.

Cooley advised Halcyon on its $100 million Series C funding. Partner Derek Colla led the Cooley team advising Halcyon, an organization devoted to defeating ransomware through prevention and resilience by way of a proprietary technology that captures encryption keys, enabling organizations to recover from attacks in minutes without paying ransom.

Cooley advised Expert Institute (EI), a provider of outsourced legal services to the attorney market, on its acquisition by Levine Leichtman Capital Partners, a Los Angeles-based private equity firm, from Spectrum Equity, a growth equity firm that provides capital and strategic support to innovative companies in the information economy, in partnership with management.